AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
Retrieved on:
Thursday, December 7, 2023
Medical Devices, Health, Hospitals, Clinical Trials, Cardiology, Biotechnology, UCLA, Interventional radiology, Pulmonary embolism, Associate, MMA, Safety, APEX, Assistant professor, Literature, Mortality, CDT, Patient, PERT, Acute, MD, Cancer, Trial of the century, Partnership, Travel, Deep vein thrombosis, Medical imaging, Dentistry, Surgery
APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company’s AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute intermediate-risk pulmonary embolism (PE).
Key Points:
- APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company’s AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute intermediate-risk pulmonary embolism (PE).
- The primary efficacy endpoint of the APEX-AV Study is the reduction in RV/LV ratio between baseline and 48 hours post-procedure.
- “The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism.
- AngioDynamics initiated the APEX-AV Study in partnership with the widely respected Pulmonary Embolism Response Team (PERT) Consortium™.